Generation and biological activities of oxidized phospholipids

Antioxidants and Redox Signaling

Volumn 12, Issue 8, 2010, Pages 1009-1059

  Bochkov, Valery N ^a   Oskolkova, Olga V ^a   Birukov, Konstantin G ^b   Levonen, Anna Liisa ^c   Binder, Christoph J ^d   Stöckl, Johannes ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1 MIMETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM ION; CELL ADHESION MOLECULE; CHEMOKINE; CYCLIC AMP; FREE RADICAL; FURAN DERIVATIVE; GLYCEROPHOSPHOLIPID; GUANOSINE TRIPHOSPHATASE; HIGH DENSITY LIPOPROTEIN MIMETIC PEPTIDE; HYDROPEROXIDE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; PEPTIDE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXY RADICAL; PHOSPHATASE; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN RECEPTOR; PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACUTE LUNG INJURY; ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTHRAX; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; BLOOD CLOTTING; CELL ADHESION; CELL FUNCTION; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CELL STRESS; CLONAL ANERGY; CYCLIZATION; CYTOSKELETON; DENDRITIC CELL; DISEASE MARKER; DRUG MECHANISM; ELECTROPHILIC STRESS; ESTERIFICATION; FOCAL ADHESION; GAP JUNCTION; GENE INDUCTION; HALOGENATION; HUMAN; IMMUNIZATION; INFLAMMATION; INFLUENZA VIRUS A H5N1; ISCHEMIA; LEPROSY; LEUKOCYTE; LIGHT EXPOSURE; LUNG INJURY; MULTIPLE SCLEROSIS; NITRATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; REDUCTION; RESPIRATORY BURST; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; TIGHT JUNCTION; ULTRAVIOLET RADIATION; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD COAGULATION; CDC42 GTP-BINDING PROTEIN; CYTOSKELETON; HUMANS; IMMUNE SYSTEM PROCESSES; LIPID PEROXIDATION; LUNG; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHOLIPIDS; PLATELET ACTIVATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, SCAVENGER; SIGNAL TRANSDUCTION;

EID: 77949618571     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2597     Document Type: Review

References (396)

1. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, and Iida M. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 109: 227-233, 2004.
2. Alcaraz MJ, Fernandez P, and Guillen MI. Anti-inflammatory actions of the heme oxygenase-1 pathway. Curr Pharm Des 9: 2541-2551, 2003.
3. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, Shah PK, and Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Ar-terioscler Thromb Vasc Biol 16: 1074-1079, 1996.
4. Androulakis N, Durand H, Ninio E, and Tsoukatos DC. Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation. J Lipid Res 46: 1923-1932, 2005.
5. Anton R, Camacho M, Puig L, and Vila L. Hepoxilin B3 and its enzymatically formed derivative trioxilin B3 are incorporated into phospholipids in psoriatic lesions. J Invest Dermatol 118: 139-146, 2002.
6. Arai M, Imai H, Metori A, and Nakagawa Y. Preferential esterification of endogenously formed 5-hydroxyeicos-atetraenoic acid to phospholipids in activated polymor-phonuclear leukocytes. Eur J Biochem 244: 513-519, 1997.
7. Arthur WT, Quilliam LA, and Cooper JA. Rap1 promotes cell spreading by localizing Rac guanine nucleotide exchange factors. J Cell Biol 167: 111-122, 2004.
8. Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, and Woodruff TM. Toll-like receptors in ischemia-reperfusion injury. Shock 32: 4-16, 2009.
9. Asai A, Okajima F, Nakagawa K, Ibusuki D, Tanimura K, Nakajima Y, Nagao M, Sudo M, Harada T, Miyazawa T, and Oikawa S. Phosphatidylcholine hydroperoxide-induced THP-1 cell adhesion to intracellular adhesion molecule-1. J Lipid Res 50: 9557-9965, 2009.
10. Ashraf MZ, Kar NS, Chen X, Choi J, Salomon RG, Febbraio M, and Podrez EA. Specific oxidized phospholipids inhibit scavenger receptor bi-mediated selective uptake of choles-teryl esters. J Biol Chem 283: 10408-10414, 2008.
11. Ashraf MZ, Kar NS, and Podrez EA. Oxidized phospho-lipids: Biomarker for cardiovascular diseases. Int J Biochem Cell Biol 41: 1241-1244, 2009.
12. Baier J, Maisch T, Maier M, Landthaler M, and Baumler W. Direct detection of singlet oxygen generated by UVA irradiation in human cells and skin. J Invest Dermatol 127: 1498-1506, 2007.
13. Baker PR, Schopfer FJ, Sweeney S, and Freeman BA. Red cell membrane and plasma linoleic acid nitration products: Synthesis, clinical identification, and quantitation. Proc Natl Acad Sci USA 101: 11577-11582, 2004.
14. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, and Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343, 1996.
15. Bayir H, Tyurin VA, Tyurina YY, Viner R, Ritov V, Amoscato AA, Zhao Q, Zhang XJ, Janesko-Feldman KL, Alexander H, Basova LV, Clark RS, Kochanek PM, and Kagan VE. Selective early cardiolipin peroxidation after traumatic brain injury: An oxidative lipidomics analysis. Ann Neurol 62: 154-169, 2007.
16. Belkner J, Wiesner R, Rathman J, Barnett J, Sigal E, and Kuhn H. Oxygenation of lipoproteins by mammalian li-poxygenases. Eur J Biochem 213: 251-261, 1993.
17. Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, Binder CJ, Horkko S, Krauss RM, Chapman MJ, Witztum JL, and Tsimikas S. A novel function of lipopro-tein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 49: 2230-2239, 2008.
18. Berliner JA and Gharavi NM. Endothelial cell regulation by phospholipid oxidation products. Free Radic Biol Med 45: 119-123, 2008.
19. Berliner JA, Leitinger N, and Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J Lipid Res 50: S207-S212, 2009.
20. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, and Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 11: 142-147, 2001.
21. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, and Fogelman AM. Minimally modified low density lipoprotein stimulates mono-cyte endothelial interactions. J Clin Invest 85: 1260-1266, 1990.
22. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, and Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med 8: 1218-1226, 2002.
23. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M, and Witztum JL. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 114: 427-437, 2004.
24. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, and Sil-verman GJ. Pneumococcal vaccination decreases atherosclerotic lesion formation: Molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9: 736-743, 2003.
25. Binder CJ, Shaw PX, Chang MK, Boullier A, Hartvigsen K, Horkko S, Miller YI, Woelkers DA, Corr M, and Witztum JL. The role of natural antibodies in atherogenesis. J Lipid Res 46: 1353-1363, 2005.
26. Bird DA, Gillotte KL, Horkko S, Friedman P, Dennis EA, Witztum JL, and Steinberg D. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macro-phages can recognize both the modified lipid moieties and the modified protein moieties: Implications with respect to macrophage recognition of apoptotic cells. Proc Natl Acad Sci USA 96: 6347-6352, 1999.
27. Birkle DL and Bazan NG. Effect of K\+ depolarization on the synthesis of prostaglandins and hydroxyeicosatetra-(5,8,11,14)enoic acids (HETE) in the rat retina. Evidence for esterification of 1 2-HETE in lipids. Biochim Biophys Acta 795: 564-573, 1984.
28. Birukov KG, Bochkov VN, Birukova AA, Kawkitinarong K, Rios A, Leitner A, Verin AD, Bokoch GM, Leitinger N, and Garcia JG. Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac. Circ Res 95: 892-901, 2004.
29. Birukov KG, Leitinger N, Bochkov VN, and Garcia JG. Signal transduction pathways activated in human pulmonary endothelial cells by OxPAPC, a bioactive component of oxidized lipoproteins. Micro vasc Res 67: 18-28, 2004.
30. Birukova AA, Chatchavalvanich S, Oskolkova O, Bochkov VN, and Birukov KG. Signaling pathways involved in OxPAPC-induced pulmonary endothelial barrier protection. Micro vasc Res 73: 173-181, 2007.
31. Birukova AA, Fu P, Chatchavalvanich S, Burdette D, Os-kolkova O, Bochkov VN, and Birukov KG. Polar head groups are important for barrier-protective effects of oxidized phospholipids on pulmonary endothelium. Am J Physiol Lung Cell Mol Physiol 292: L924-L935, 2007.
32. Birukova AA, Malyukova I, Mikaelyan A, Fu P, and Bir-ukov KG. Tiam1 and betaPIX mediate Rac-dependent en-dothelial barrier protective response to oxidized phospholipids. J Cell Physiol 211: 608-617, 2007.
33. Birukova AA, Malyukova I, Poroyko V, and Birukov KG. Paxillin-beta- catenin interactions are involved in Rac= Cdc42-mediated endothelial barrier-protective response to oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol 293: L1 99-L211, 2007.
34. Birukova AA, Zagranichnaya T, Fu P, Alekseeva E, Chen W, Jacobson JR, and Birukov KG. Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA-and Epac1=Rap1-dependent Rac activation. Exp Cell Res 313: 2504-2520, 2007.
35. Bishop AL and Hall A. Rho GTPases and their effector proteins. Biochem J 348: 241-255, 2000.
36. Bluml S, Kirchberger S, Bochkov VN, Kronke G, Stuhlmeier K, Majdic O, Zlabinger GJ, Knapp W, Binder BR, Stockl J, and Leitinger N. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol 175: 501-508, 2005.
37. Bluml S, Rosc B, Lorincz A, Seyerl M, Kirchberger S, Os-kolkova O, Bochkov VN, Majdic O, Ligeti E, and Stockl J. The oxidation state of phospholipids controls the oxidative burst in neutrophil granulocytes. J Immunol 181: 4347-4353, 2008.
38. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, and Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419: 77-81, 2002.
39. Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, Hofer E, Binder BR, and Leitinger N. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK=EGR-1 and Ca(\+\+)=NFAT. Blood 99: 199-206, 2002.
40. Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, Afonyushkin T, Gruber F, Breuss J, Minchenko A, Mechtcheriakova D, Hohensinner P, Ry-chli K, Wojta J, Resink T, Erne P, Binder BR, and Leitinger N. Oxidized phospholipids stimulate angiogenesis via au-tocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res 99: 900-908, 2006.
41. Boguski MS and McCormick F. Proteins regulating Ras and its relatives. Nature 366: 643-654, 1993.
42. Bonser RW, Siegel MI, Chung SM, McConnell RT, and Cuatrecasas P. Esterification of an endogenously synthesized lipoxygenase product into granulocyte cellular lipids. Biochemistry 20: 5297-5301, 1981.
43. Borisy GG and Svitkina TM. Actin machinery: pushing the envelope. Curr Opin Cell Biol 12: 104-112, 2000.
44. Borst JW, Visser NV, Kouptsova O, and Visser AJ. Oxidation of unsaturated phospholipids in membrane bilayer mixtures is accompanied by membrane fluidity changes. Biochim Biophys Acta 1487: 61-73, 2000.
45. Boulanger CM, Amabile N, and Tedgui A. Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension 48: 180-186, 2006.
46. Boullier A, Friedman P, Harkewicz R, Hartvigsen K, Green SR, Almazan F, Dennis EA, Steinberg D, Witztum JL, and Quehenberger O. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res 46: 969-976, 2005.
47. Brame CJ, Boutaud O, Davies SS, Yang T, Oates JA, Roden D, and Roberts LJ. Modification of proteins by isoketal-containing oxidized phospholipids. J Biol Chem 279: 13447-13451, 2004.
48. Briles DE, Forman C, Hudak S, and Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 156: 1177-1185, 1982.
49. Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, Witztum JL, Fuster V, Tsimikas S, and Fayad ZA. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 117: 3206-3215, 2008.
50. Brooks JD, Milne GL, Yin H, Sanchez SC, Porter NA, and Morrow JD. Formation of highly reactive cyclopentenone isoprostane compounds (A3=J3-isoprostanes) in vivo from eicosapentaenoic acid. J Biol Chem 283: 12043-12055, 2008.
51. Byun J, Mueller DM, Fabjan JS, and Heinecke JW. Nitrogen dioxide radical generated by the myeloperoxidase-hydrogen peroxide-nitrite system promotes lipid perox-idation of low density lipoprotein. FEBS Lett 455: 243-246, 1999.
52. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, Kohler HV, Kaveri SV, and Nicoletti A. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 50: 540-546, 2007.
53. Carr AC, Winterbourn CC, and van den Berg JJ. Peroxidase-mediated bromination of unsaturated fatty acids to form bromohydrins. Arch Biochem Biophys 327: 227-233, 1996.
54. Chahdi A, Miller B, and Sorokin A. Endothelin 1 induces beta 1 Pix translocation and Cdc42 activation via protein kinase A-dependent pathway. J Biol Chem 280: 578-584, 2005.
55. Chang MK, Bergmark C, Laurila A, Horkko S, Han KH, Friedman P, Dennis EA, and Witztum JL. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: Evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA 96: 6353-6358, 1999.
56. Chang MK, Binder CJ, Miller YI, Subbanagounder G, Sil-verman GJ, Berliner JA, and Witztum JL. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 200: 1359-1370, 2004.
57. Chang MK, Binder CJ, Torzewski M, and Witztum JL. C-reactive protein binds to both oxidized LDL and apo-ptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99: 13043-13048, 2002.
58. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD, and Chen CH. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: Mediator role of platelet-activating factor-like phospholipids. Circulation 104: 588-593, 2001.
59. Chen H, Bernstein BW, and Bamburg JR. Regulating actin-filament dynamics in vivo. Trends Biochem Sci 25: 19-23, 2000.
60. Chen K, Febbraio M, Li W, and Silverstein RL. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ Res 102: 1512-1519, 2008.
61. Chen R, Yang L, and McIntyre TM. Cytotoxic phospholipid oxidation products. Cell death from mitochondrial damage and the intrinsic caspase cascade. J Biol Chem 282: 24842-24850, 2007.
62. Chen Y, Morrow JD, and Roberts LJ. Formation of reactive cyclopentenone compounds in vivo as products of the iso-prostane pathway. J Biol Chem 274: 10863-10868, 1999.
63. Chen Y, Wang Y, Yu H, Wang F, and Xu W. The cross talk between protein kinase A-and RhoA-mediated signaling in cancer cells. Exp Biol Med (Maywood) 230: 731-741, 2005.
64. Cheng C, Noordeloos AM, Jeney V, Soares MP, Moll F, Pasterkamp G, Serruys PW, and Duckers HJ. Heme oxy-genase 1 determines atherosclerotic lesion progression into a vulnerable plaque. Circulation 119: 3017-3027, 2009.
65. Cherepanova OA, Pidkovka NA, Sarmento OF, Yoshida T, Gan Q, Adiguzel E, Bendeck MP, Berliner J, Leitinger N, and Owens GK. Oxidized phospholipids induce type VIII collagen expression and vascular smooth muscle cell migration. Circ Res 104: 609-618, 2009.
66. Chisolm GM and Steinberg D. The oxidative modification hypothesis of atherogenesis: An overview. Free Radic Biol Med 28: 1815-1826, 2000.
67. Cole AL, Subbanagounder G, Mukhopadhyay S, Berliner JA, and Vora DK. Oxidized phospholipid-induced endo-thelial cell=monocyte interaction is mediated by a cAMPdependent R-Ras/PI3-kinase pathway. Arterioscler Thromb Vasc Biol 23: 1384-1390, 2003.
68. Conrad M, Schneider M, Seiler A, and Bornkamm GW. Physiological role of phospholipid hydroperoxide glutathione peroxidase in mammals. Biol Chem 388: 1019-1025, 2007.
69. Costello PB, Baer AN, and Green FA. Saturability of es-terification pathways of major monohydroxyeicosat-etraenoic acids in rat basophilic leukemia cells. Inflammation 15: 269-279, 1991.
70. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, Gutierrez MA, Navab M, Reddy ST, Witztum JL, Fogelman AM, Rea TH, Eisenberg D, Berliner J, and Modlin RL. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest 118: 2917-2928, 2008.
71. Davies SS, Amarnath V, Brame CJ, Boutaud O, and Roberts LJ. Measurement of chronic oxidative and inflammatory stress by quantification of isoketal/levuglandin gamma-ketoaldehyde protein adducts using liquid chromatography tandem mass spectrometry. Nat Protoc 2: 2079-2091, 2007.
72. Davies SS, Pontsler AV, Marathe GK, Harrison KA, Murphy RC, Hinshaw JC, Prestwich GD, Hilaire AS, Prescott SM, Zimmerman GA, and McIntyre TM. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator- activated receptor gamma ligands and agonists. J Biol Chem 276: 16015-16023, 2001.
73. Davis B, Koster G, Douet LJ, Scigelova M, Woffendin G, Ward JM, Smith A, Humphries J, Burnand KG, Macphee CH, and Postle AD. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J Biol Chem 283: 6428-6437, 2008.
74. Deguchi H, Fernandez JA, Hackeng TM, Banka CL, and Griffin JH. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci USA 97: 1743-1748, 2000.
75. Deigner HP and Hermetter A. Oxidized phospholipids: Emerging lipid mediators in pathophysiology. Curr Opin Lipidol 19: 289-294, 2008.
76. Dejana E. Endothelial cell-cell junctions: Happy together. Nat Rev Mol Cell Biol 5: 261-270, 2004.
77. Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, and Staels B. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett 471: 34-38, 2000.
78. DeMaio L, Rouhanizadeh M, Reddy S, Sevanian A, Hwang J, and Hsiai TK. Oxidized phospholipids mediate occludin expression and phosphorylation in vascular endothelial cells. Am J Physiol Heart Circ Physiol 290: H674-H683, 2006.
79. Dever GJ, Benson R, Wainwright CL, Kennedy S, and Spickett CM. Phospholipid chlorohydrin induces leukocyte adhesion to ApoE ~' mouse arteries via upregulation of P-selectin. Free Radic Biol Med 44: 452-463, 2008.
80. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, and Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99: 11908-11913, 2002.
81. Domingues MR, Reis A, and Domingues P. Mass spectrometry analysis of oxidized phospholipids. Chem Phys Lipids 156: 1-12, 2008.
82. Edelstein C, Pfaffinger D, Hinman J, Miller E, Lipkind G, Tsimikas S, Bergmark C, Getz GS, Witztum JL, and Scanu AM. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 278: 52841-52847, 2003.
83. Erridge C, Kennedy S, Spickett CM, and Webb DJ. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: Roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J Biol Chem 283: 24748-24759, 2008.
84. Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128, 1991.
85. Etienne-Manneville S and Hall A. Integrin-mediated activation of Cdc42 controls cell polarity in migrating astro-cytes through PKCzeta. Cell 106: 489-498, 2001.
86. Fang X, Kaduce TL, Weintraub NL, and Spector AA. Cy-tochrome P450 metabolites of arachidonic acid: Rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells. Prostaglandins Leukot Essent Fatty Acids 57: 367-371, 1997.
87. Faria-Neto JR, Chyu KY, Li X, Dimayuga PC, Ferreira C, Yano J, Cercek, and Shah PK. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipopro-tein E-null mice. Atherosclerosis 189: 83-90, 2006.
88. Fathman CG and Lineberry NB. Molecular mechanisms of CD4\+ T-cell anergy. Nat Rev Immunol 7: 599-609, 2007.
89. Febbraio M, Hajjar DP, and Silverstein RL. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108: 785-791, 2001.
90. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, and Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105: 1049-1056, 2000.
91. Fei H, Berliner JA, Parhami F, and Drake TA. Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler Thromb 13: 1711-1717, 1993.
92. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX, Kuriakose G, Fisher EA, Marks AR, Ron D, and Tabas I. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 5: 781-792, 2003.
93. Fessel JP, Hulette C, Powell S, Roberts LJ, and Zhang J. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem 85: 645-650, 2003.
94. Fessel JP, Porter NA, Moore KP, Sheller JR, and Roberts LJ. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci USA 99: 16713-16718, 2002.
95. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, and Tsimikas S. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol 53: 2186-2196, 2009.
96. Freigang S, Horkko S, Miller E, Witztum JL, and Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neo-epitopes. Arterioscler Thromb Vasc Biol 18: 1972-1982, 1998.
97. Frey B, Haupt R, Alms S, Holzmann G, Konig T, Kern H, Kox W, Rustow B, and Schlame M. Increase in fragmented phosphatidylcholine in blood plasma by oxidative stress. J Lipid Res 41: 1145-1153, 2000.
98. Friedman P, Horkko S, Steinberg D, Witztum JL, and Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phos-pholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem 277: 7010-7020, 2002.
99. Frostegard J, Svenungsson E, Wu R, Gunnarsson I, Lund-berg IE, Klareskog L, Horkko S, and Witztum JL. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52: 192-200, 2005.
100. Fukai M, Hayashi T, Yokota R, Shimamura T, Suzuki T, Taniguchi M, Matsushita M, Furukawa H, and Todo S. Lipid peroxidation during ischemia depends on ischemia time in warm ischemia and reperfusion of rat liver. Free Radic Biol Med 38: 1372-1381, 2005.
101. Furnkranz A, Schober A, Bochkov VN, Bashtrykov P, Kronke G, Kadl A, Binder BR, Weber C, and Leitinger N. Oxidized phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler Thromb Vasc Biol 25: 633-638, 2005.
102. Gallon AA and Pryor WA. The reaction of low levels of nitrogen dioxide with methyl linoleate in the presence and absence of oxygen. Lipids 29: 171-176, 1994.
103. Gao L, Zackert WE, Hasford JJ, Danekis ME, Milne GL, Remmert C, Reese J, Yin H, Tai HH, Dey SK, Porter NA, and Morrow JD. Formation of prostaglandins E2 and D2 via the isoprostane pathway: A mechanism for the generation of bioactive prostaglandins independent of cycloox-ygenase. J Biol Chem 278: 28479-28489, 2003.
104. Gao S, Zhang R, Greenberg ME, Sun M, Chen X, Levison BS, Salomon RG, and Hazen SL. Phospholipid hydro-xyalkenals, a subset of recently discovered endogenous CD36 ligands, spontaneously generate novel furan-containing phospholipids lacking CD36 binding activity in vivo. J Biol Chem 281: 31298-31308, 2006.
105. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, and English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108: 689-701, 2001.
106. Gargalovic PS, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, Truong A, Baruch-Oren T, Berliner JA, Kirchgessner TG, and Lusis AJ. The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. Arterioscler Thromb Vasc Biol 26: 2490-2496, 2006.
107. Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, Truong A, Patel S, Nelson SF, Horvath S, Berliner JA, Kirchgessner TG, and Lusis AJ. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci USA 103: 12741-12746, 2006.
108. Gasser H, Hallstrom S, Redl H, and Schlag G. Oxidatively modified plasma phospholipids containing reactive car-bonyl functions measured by HPLC: Evidence for phos-phatidylcholine-bound aldehydes in plasma of burn patients. Free Radic Res 22: 327-336, 1995.
109. Geiger B and Bershadsky A. Assembly and mechanosensory function offocal contacts. Curr Opin Cell Biol 13: 584-592, 2001.
110. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, Kopolovic Y, Wick G, Shoenfeld Y, and Harats D. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138: 147-152, 1998.
111. Gershov D, Kim S, Brot N, and Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an an-tiinflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med 192: 1353-1364, 2000.
112. Gharavi NM, Alva JA, Mouillesseaux KP, Lai C, Yeh M, Yeung W, Johnson J, Szeto WL, Hong L, Fishbein M, Wei L, Pfeffer LM, and Berliner JA. Role of the Jak=STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 282: 31460-31468, 2007.
113. Gharavi NM, Baker NA, Mouillesseaux KP, Yeung W, Honda HM, Hsieh X, Yeh M, Smart EJ, and Berliner JA. Role of endothelial nitric oxide synthase in the regulation of SREBP activation by oxidized phospholipids. Circ Res 98: 768-776, 2006.
114. Gharavi NM, Gargalovic PS, Chang I, Araujo JA, Clark MJ, Szeto WL, Watson AD, Lusis AJ, and Berliner JA. High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory. Arterioscler Thromb Vasc Biol 27: 1346-1353, 2007.
115. Gillotte-Taylor K, Boullier A, Witztum JL, Steinberg D, and Quehenberger O. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res 42: 1474-1482, 2001.
116. Girotti AW and Kriska T. Role of lipid hydroperoxides in photo-oxidative stress signaling. Antioxid Redox Signal 6: 301-310, 2004.
117. Gniwotta C, Morrow JD, Roberts LJ, and Kuhn H. Pros-taglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 17: 3236-3241, 1997.
118. Gopfert MS, Siedler F, Siess W, and Sellmayer A. Structural identification of oxidized acyl-phosphatidylcholines that induce platelet activation. J Vasc Res 42: 120-132, 2005.
119. Govindarajan B, Laird J, Salomon RG, and Bhattacharya SK. Isolevuglandin-modified proteins, including elevated levels of inactive calpain-1, accumulate in glaucomatous trabecular meshwork. Biochemistry 47: 817-825, 2008.
120. Goyal J, Wang K, Liu M, and Subbaiah PV. Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. J Biol Chem 272: 16231-16239, 1997.
121. Greenberg ME, Li XM, Gugiu BG, Gu X, Qin J, Salomon RG, and Hazen SL. The lipid whisker model of the structure of oxidized cell membranes. J Biol Chem 283: 2385-2396, 2008.
122. Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, and Hazen SL. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med 203: 2613-2625, 2006.
123. Groeneweg M, Vergouwe MN, Scheffer PG, Vermue HP, Sollewijn G, Sijbers AM, Leitinger N, Hofker MH, and de Winther MP. Modification of LDL with oxidized 1-palmi-toyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (ox-PAPC) results in a novel form of minimally modified LDL that modulates gene expression in macrophages. Biochim Biophys Acta 1781: 336-343, 2008.
124. Gruber F, Oskolkova O, Leitner A, Mildner M, Mlitz V, LengauerB,Kadl A,Mrass P, Kronke G, Binder BR, Bochkov VN, Leitinger N, and Tschachler E. Photooxidation generates biologically active phospholipids that induce heme oxygenase-1 in skin cells. J Biol Chem 282: 16934-16941, 2007.
125. Gu X, Sun M, Gugiu B, Hazen S, Crabb JW, and Salomon RG. Oxidatively truncated docosahexaenoate phospholip-ids: Total synthesis, generation, and peptide adduction chemistry. J Org Chem 68: 3749-3761, 2003.
126. Gu X, Zhang W, and Salomon RG. Fe2\+ catalyzes vitamin E-induced fragmentation of hydroperoxy and hydroxy endoperoxides that generates gamma-hydroxy alkenals. J Am Chem Soc 129: 6088-6089, 2007.
127. Gugiu BG, Mesaros CA, Sun M, Gu X, Crabb JW, and Salomon RG. Identification of oxidatively truncated etha-nolamine phospholipids in retina and their generation from polyunsaturated phosphatidylethanolamines. Chem Res Toxicol 19: 262-271, 2006.
128. Gugiu BG, Mouillesseaux K, Duong V, Herzog T, Heki-mian A, Koroniak L, Vondriska TM, and Watson AD. Protein targets of oxidized phospholipids in endothelial cells. J Lipid Res 49: 510-520, 2008.
129. Han KH, Chang MK, Boullier A, Green SR, Li A, Glass CK, and Quehenberger O. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest 106: 793-802, 2000.
130. Hartwich J, Dembinska-Kiec A, Gruca A, Motyka M, Par-tyka L, Skrzeczynska J, Bzowska M, Pryjma J, Huber J, Leitinger N, and Schmitz G. Regulation of platelet adhesion by oxidized lipoproteins and oxidized phospholipids. Platelets 13: 141-151, 2002.
131. Haseruck N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, and Siess W. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: Involvement of P2Y1 and P2Y12 receptors. Blood 103: 2585-2592, 2004.
132. Hattori M, Arai H, and Inoue K. Purification and characterization of bovine brain platelet-activating factor acet-ylhydrolase. J Biol Chem 268: 18748-18753, 1993.
133. Hazen SL. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J Biol Chem 283: 15527-15531, 2008.
134. Herbrand U and Ahmadian MR. p190-RhoGAP as an integral component of the Tiam1=Rac1-induced down-regulation of Rho. Biol Chem 387: 311-317, 2006.
135. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zahringer U, and Beutler B. CD36 is a sensor of diacylglycerides. Nature 433: 523-527, 2005.
136. Hoff HF, O'Neil J, Wu Z, Hoppe G, and Salomon RL. Phospholipid hydroxyalkenals: Biological and chemical properties of specific oxidized lipids present in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 23: 275-282, 2003.
137. Holland R, Hawkins AE, Eggler AL, Mesecar AD, Fabris D, and Fishbein JC. Prospective type 1 and type 2 disulfides of Keap1 protein. Chem Res Toxicol 21: 2051-2060, 2008.
138. Honda HM, Leitinger N, Frankel M, Goldhaber JI, Natarajan R, Nadler JL, Weiss JN, and Berliner JA. Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler Thromb Vasc Biol 19: 680-686, 1999.
139. Horkko S, Binder CJ, Shaw PX, Chang MK, Silverman G, Palinski W, and Witztum JL. Immunological responses to oxidized LDL. Free Radic Biol Med 28: 1771-1779, 2000.
140. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Sub-banagounder G, Berliner JA, Friedman P, Dennis EA, Curtiss LK, Palinski W, and Witztum JL. Monoclonal au-toantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103: 117-128, 1999.
141. Horkko S, Miller E, Branch DW, Palinski W, and Witztum JL. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc Nat! Acad Sci USA 94: 10356-10361, 1997.
142. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, and Witztum JL. Antiphospholipid
143. Hosoya T, Maruyama A, Kang MI, Kawatani Y, Shibata T, Uchida K, Warabi E, Noguchi N, Itoh K, and Yamamoto M. Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J Biol Chem 280: 27244-27250, 2005.
144. Hsiai TK, Cho SK, Reddy S, Hama S, Navab M, Demer LL, Honda HM, and Ho CM. Pulsatile flow regulates monocyte adhesion to oxidized lipid-induced endothelial cells. Ar-terioscler Thromb Vasc Bio! 21: 1770-1776, 2001.
145. Huang LS, Kang JS, Kim MR, and Sok DE. Oxygenation of arachidonoyl lysophospholipids by lipoxygenases from soybean, porcine leukocyte, or rabbit reticulocyte. J Agric Food Chem 56: 1224-1232, 2008.
146. Huang MS, Lu J, Ivanov Y, Sage AP, Tseng W, Demer LL, and Tintut Y. Hyperlipidemia impairs osteoanabolic effects of PTH. J Bone Miner Res 23: 1672-1679, 2008.
147. Huang MS, Morony S, Lu J, Zhang Z, Bezouglaia O, Tseng W, Tetradis S, Demer LL, and Tintut Y. Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts. J Biol Chem 282: 21237-21243, 2007.
148. Huang Z, Jiang J, Tyurin VA, Zhao Q, Mnuskin A, Ren J, Belikova NA, Feng W, Kurnikov IV, and Kagan VE. Car-diolipin deficiency leads to decreased cardiolipin perox-idation and increased resistance of cells to apoptosis. Free Radic Biol Med 44: 1935-1944, 2008.
149. Huber J, Furnkranz A, Bochkov VN, Patricia MK, Lee H, Hedrick CC, Berliner JA, Binder BR, and Leitinger N. Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase. J Lipid Res 47: 1054-1062, 2006.
150. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Witztum JL, Binder BR, and Leitinger N. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol 22: 101-107, 2002.
151. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development. Clinical and animal studies. Clin Chim Acta 348: 1-8, 2004.
152. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perk-mann T, van LG, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, Liu H, Sun Y, Pasparakis M, Kopf M, Mech C, Bavari S, Peiris JS, Slutsky AS, Akira S, Hultqvist M, Holmdahl R, Nicholls J, Jiang C, Binder CJ, and Penninger JM. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133: 235-249, 2008.
153. Imbusch R and Mueller MJ. Formation of isoprostane F(2)-like compounds (phytoprostanes F(1)) from alpha-linolenic acid in plants. Free Radic Biol Med 28: 720-726, 2000.
154. Isakson BE, Kronke G, Kadl A, Leitinger N, and Duling BR. Oxidized phospholipids alter vascular connexin expression, phosphorylation, and heterocellular communication. Arterioscler Thromb Vasc Biol 26: 2216-2221, 2006.
155. Ishii H, Tezuka T, Ishikawa H, Takada K, Oida K, and Horie S. Oxidized phospholipids in oxidized low-density lipoprotein down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RARbeta-RXRalpha heterodimers and Sp1 and Sp3 to their binding sequences in the TM promoter. Blood 101: 4765-4774, 2003.
156. Ishikawa K, Navab M, Leitinger N, Fogelman AM, and Lusis AJ. Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL. J Clin Invest 100: 1209-1216, 1997.
157. Jerlich A, Pitt AR, Schaur RJ, and Spickett CM. Pathways of phospholipid oxidation by HOCl in human LDL detected by LC-MS. Free Radic Biol Med 28: 673-682, 2000.
158. JerlichA,Schaur RJ, Pitt AR, and Spickett CM. The formation of phosphatidylcholine oxidation products by stimulated phagocytes. Free Radic Res 37: 645-653, 2003.
159. Jin Y and Penning TM. Aldo-keto reductases and bioactivation= detoxication. Annu Rev Pharmacol Toxicol 47: 263-292, 2007.
160. Jyrkkanen HK, Kansanen E, Inkala M, Kivela AM, Hurttila H, Heinonen SE, Goldsteins G, Jauhiainen S, Tiainen S, Makkonen H, Oskolkova O, Afonyushkin T, Koistinaho J, Yamamoto M, Bochkov VN, Yla-Herttuala S, and Levonen AL. Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo. Circ Res 103: e1-e9, 2008.
161. Kadl A, Galkina E, and Leitinger N. Induction of CCR2-dependent macrophage accumulation by oxidized phos-pholipids in the air-pouch model of inflammation. Arthritis Rheum 60: 1362-1371, 2009.
162. Kadl A, Huber J, Gruber F, Bochkov VN, Binder BR, and Leitinger N. Analysis of inflammatory gene induction by oxidized phospholipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. Vascul Pharmacol 38: 219-227, 2002.
163. Kagan VE, Bayir HA, Belikova NA, Kapralov O, Tyurina YY, Tyurin VA, Jiang J, Stoyanovsky DA, Wipf P, Kochanek PM, Greenberger JS, Pitt B, Shvedova AA, and Borisenko G. Cytochrome c=cardiolipin relations in mitochondria: A kiss of death. Free Radic Biol Med 46: 1439-1453, 2009.
164. Kagan VE, Borisenko GG, Tyurina YY, Tyurin VA, Jiang J, Potapovich AI, Kini V, Amoscato AA, and Fujii Y. Oxida-tive lipidomics of apoptosis: Redox catalytic interactions of cytochrome c with cardiolipin and phosphatidylserine. Free Radic Biol Med 37: 1963-1985, 2004.
165. Kagan VE, Tyurin VA, Jiang J, Tyurina YY, Ritov VB, Amoscato AA, Osipov AN, Belikova NA, Kapralov AA, Kini V, Vlasova II, Zhao Q, Zou M, Di P, Svistunenko DA, Kurnikov IV, and Borisenko GG. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol 1: 223-232, 2005.
166. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, and Robinson WH. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 12: 138-143, 2006.
167. Kar NS, Ashraf MZ, Valiyaveettil M, and Podrez EA. Mapping and characterization of the binding site for specific oxidized phospholipids and oxidized low density li-poprotein of scavenger receptor CD36. J Biol Chem 283: 8765-8771, 2008.
168. Karara A, Dishman E, Falck JR, and Capdevila JH. Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized ara-chidonate moieties. J Biol Chem 266: 7561-7569, 1991.
169. Karvonen J, Paivansalo M, Kesaniemi YA, and Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108: 2107-2112, 2003.
170. Katsumi A, Orr AW, Tzima E, and Schwartz MA. Integrins in mechano-transduction. J Biol Chem 279: 12001-12004, 2004.
171. Kawai Y, Kiyokawa H, Kimura Y, Kato Y, Tsuchiya K, and Terao J. Hypochlorous acid-derived modification of phos-pholipids: Characterization of amino phospholipids as regulatory molecules for lipid peroxidation. Biochemistry 45: 14201-14211, 2006.
172. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
173. Khallou-Laschet J, Tupin E, Caligiuri G, Poirier B, Thie-blemont N, Gaston AT, Vandaele M, Bleton J, Tchapla A, Kaveri SV, Rudling M and Nicoletti A. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis 184: 330-341, 2006.
174. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL and Tsimikas S. Oxidized phospholipids, li-poprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: Prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27: 1788-1795, 2007.
175. Kim JA, Territo MC, Wayner E, Carlos TM, Parhami F, Smith CW, Haberland ME, Fogelman AM, and Berliner JA. Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Ar-terioscler Thromb 14: 427-433, 1994.
176. Kinnunen PK. Lipid bilayers as osmotic response elements. Cell Physiol Biochem 10: 243-250, 2000.
177. Knapp S, Matt U, Leitinger N, and van der PT. Oxidized phospholipids inhibit phagocytosis and impair outcome in gram-negative sepsis in vivo. J Immunol 178: 993-1001, 2007.
178. Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Ka-neko H, Nakayama Y, Eguchi M, Wada Y, Kumagai Y, and Yamamoto M. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol 29: 493-502, 2009.
179. Kono N, Inoue T, Yoshida Y, Sato H, Matsusue T, Itabe H, Niki E, Aoki J, and Arai H. Protection against oxidative.
180. Kriska T, Marathe GK, Schmidt JC, McIntyre TM, and Girotti AW. Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides. J Biol Chem 282: 100-108, 2007.
181. Kronke G, Bochkov VN, Huber J, Gruber F, Bluml S, Furnkranz A, Kadl A, Binder BR, and Leitinger N. Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein. J Biol Chem 278: 51006-51014, 2003.
182. Kuhn H, Belkner J, Wiesner R, and Brash AR. Oxygenation of biological membranes by the pure reticulocyte lipox-ygenase. J Biol Chem 265: 18351-18361, 1990.
183. Kuhn H, Belkner J, Zaiss S, Fahrenklemper T, and Wohlfeil S. Involvement of 15-lipoxygenase in early stages of ath-erogenesis. J Exp Med 179: 1903-1911, 1994.
184. Kuzmenko AI, Wu H, Bridges JP, and McCormack FX. Surfactant lipid peroxidation damages surfactant protein A and inhibits interactions with phospholipid vesicles. J Lipid Res 45: 1061-1068, 2004.
185. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL, FitzGerald GA, and Rader DJ. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 51: 1653-1662, 2008.
186. Lang JD, McArdle PJ, O'Reilly PJ, and Matalon S. Oxidant-antioxidant balance in acute lung injury. Chest 122: 314S-320S, 2002.
187. Lee CY, Seet RC, Huang SH, Long LH, and Halliwell B. Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke and Parkinsons disease patients. Cautions in the use of biomarkers of oxidative stress. Antioxid Redox Signal 11: 407-420, 2009.
188. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, Hama S, Borromeo C, Evans RM, Berliner JA, and Nagy L. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 87: 516-521, 2000.
189. Lee S, Gharavi NM, Honda H, Chang I, Kim B, Jen N, Li R, Zimman A, and Berliner JA. A role for NADPH oxidase 4 in the activation of vascular endothelial cells by oxidized phospholipids. Free Radic Biol Med 47: 145-151, 2009.
190. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 14: 421-430, 2003.
191. Leitinger N, Tyner TR, Oslund L, Rizza C, Sub-banagounder G, Lee H, Shih PT, Mackman N, Tigyi G, Territo MC, Berliner JA, and Vora DK. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci USA 96: 12010-12015, 1999.
192. Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A, and Boulanger CM. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 49: 772-777, 2007.
193. Lesnefsky EJ and Hoppel CL. Cardiolipin as an oxidative target in cardiac mitochondria in the aged rat. Biochim Biophys Acta 1777: 1020-1027, 2008.
194. Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, Morrow JD, and Darley-Usmar VM. Cellular mechanisms of redox cell signalling: Role of cysteine modification in controlling antioxidant defenses in response to electrophilic lipid oxidation products. Biochem J 378: 373-382, 2004.
195. Li R, Chen W, Yanes R, Lee S, and Berliner JA. OKL38 is an oxidative stress response gene stimulated by oxidized phospholipids. J Lipid Res 48: 709-715, 2007.
196. Li R, Mouillesseaux KP, Montoya D, Cruz D, Gharavi N, Dun M, Koroniak L, and Berliner JA. Identification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPC. Circ Res 98: 642-650, 2006.
197. Li Y, Schwabe RF, Vries-Seimon T, Yao PM, Gerbod-Giannone MC, Tall AR, Davis RJ, Flavell R, Brenner DA, and Tabas I. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and inter-leukin-6: Model of NF-kappaB-and map kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem 280: 21763-21772, 2005.
198. Libby P, Ridker PM, and Maseri A. Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
199. Lloberas N, Torras J, Herrero-Fresneda I, Cruzado JM, Riera M, Hurtado I, and Grinyo JM. Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxi-dant treatment. FASEB J 16: 908-910, 2002.
200. Loidl A, Sevcsik E, Riesenhuber G, Deigner HP, and Hermetter A. Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells. J Biol Chem 278: 32921-32928, 2003.
201. Lucerna M, Zernecke A, de NR, de Jager SC, Bot I, van der LC, Kholova I, Liehn EA, van Berkel TJ, Yla-Herttuala S, Weber C, and Biessen EA. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood 109: 122-129, 2007.
202. Ma Y, Malbon CC, Williams DL, and Thorngate FE. Altered gene expression in early atherosclerosis is blocked by low level apolipoprotein E. PLoS One 3: e2503, 2008.
203. Ma Z, Li J, Yang L, Mu Y, Xie W, Pitt B, and Li S. Inhibition of LPS-and CpG DNA-induced TN F-alpha response by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol 286: L808-L816, 2004.
204. Malle E, Marsche G, Arnhold J, and Davies MJ. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 1761: 392-415, 2006.
205. Malleier JM, Oskolkova O, Bochkov V, Jerabek I, Sokoli-kova B, Perkmann T, Breuss J, Binder BR, and Geiger M. Regulation of protein C inhibitor (PCI) activity by specific oxidized and negatively charged phospholipids. Blood 109: 4769-4776, 2007.
206. Malliri A, van ES, Huveneers S, and Collard JG. The Rac exchange factor Tiam1 is required for the establishment and maintenance of cadherin-based adhesions. J Biol Chem 279: 30092-30098, 2004.
207. Manevich Y and Fisher AB. Peroxiredoxin 6, a 1-Cys per-oxiredoxin, functions in antioxidant defense and lung phos-pholipid metabolism. Free Radic Biol Med 38: 1422-1432, 2005.
208. Manser E, Loo TH, Koh CG, Zhao ZS, Chen XQ, Tan L, Tan I, Leung T, and Lim L. PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. Mol Cell 1: 183-192, 1998.
209. Marathe GK, Davies SS, Harrison KA, Silva AR, Murphy RC, Castro-Faria Neto H, Prescott SM, Zimmerman GA, and McIntyre TM. Inflammatory platelet-activating factorlike phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem 274: 28395-28404, 1999.
210. Marathe GK, Prescott SM, Zimmerman GA, and McIntyre TM. Oxidized LDL contains inflammatory PAF-like phos-pholipids. Trends Cardiovasc Med 11: 139-142, 2001.
211. Marathe GK, Zimmerman GA, and McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipo-protein particles. J Biol Chem 278: 3937-3947, 2003.
212. Marathe GK, Zimmerman GA, Prescott SM, and McIntyre TM. Activation of vascular cells by PAF-like lipids in oxidized LDL. Vascul Pharmacol 38: 193-200, 2002.
213. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, and Sallusto F. Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. J Exp Med 198: 615-621, 2003.
214. Mastorikou M, Mackness M, and Mackness B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes 55: 3099-3103, 2006.
215. McEver RP and Cummings RD. Perspectives series: Cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 100: 485-491, 1997.
216. McIntyre TM, Prescott SM, and Stafforini DM. The emerging roles of PAF acetylhydrolase. J Lipid Res 50: S255-S259, 2009
217. Meg li FM and Sabatini K. Respiration state IV-generated ROS destroy the mitochondrial bilayer packing order in vitro. An EPR study. FEBS Lett 550: 185-189, 2003.
218. Megli FM and Sabatini K. Mitochondrial phospholipid bi-layer structure is ruined after liver oxidative injury in vivo. FEBS Lett 573: 68-72, 2004.
219. Mehta D and Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 86: 279-367, 2006.
220. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, Feingold KR, and Grunfeld C. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 20: 1536-1542, 2000.
221. Milne GL, Yin H, and Morrow JD. Human biochemistry of the isoprostane pathway. J Biol Chem 283: 15533-15537, 2008.
222. Milne GL, Zanoni G, Porta A, Sasi S, Vidari G, Musiek ES, Freeman ML, and Morrow JD. The cyclopentenone product of lipid peroxidation, 15-A2t-isoprostane, is efficiently metabolized by HepG2 cells via conjugation with gluta-thione. Chem Res Toxicol 17: 17-25, 2004.
223. Miyamoto S, Martinez GR, Rettori D, Augusto O, Medeiros MH, and Di MP. Linoleic acid hydroperoxide reacts with hypochlorous acid, generating peroxyl radical intermediates and singlet molecular oxygen. Proc Natl Acad Sci USA 103: 293-298, 2006.
224. Montuschi P, Barnes P, and Roberts LJ. Insights into oxi-dative stress: The isoprostanes. Curr Med Chem 14: 703-717, 2007.
225. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, McKee M, and Freeman MW. Loss of receptor-mediated lipid uptake via scavenger receptor A or.
226. Morrow JD, Awad JA, Boss HJ, Blair IA, and Roberts LJ. Noncyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 89: 10721-10725, 1992.
227. Morrow JD, Awad JA, Wu A, Zackert WE, Daniel VC, and Roberts LJ. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. J Biol Chem 271: 23185-23190, 1996.
228. Moumtzi A, Trenker M, Flicker K, Zenzmaier E, Saf R, and Hermetter A. Import and fate of fluorescent analogs of oxidized phospholipids in vascular smooth muscle cells. J Lipid Res 48: 565-582, 2007.
229. Mullins RD. How WASP-family proteins and the Arp2=3 complex convert intracellular signals into cytoskeletal structures. Curr Opin Cell Biol 12: 91-96, 2000.
230. Musiek ES, Breeding RS, Milne GL, Zanoni G, Morrow JD, and McLaughlin B. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neu-rodegeneration. J Neurochem 97: 1301-1313, 2006.
231. Mwaikambo BR, Sennlaub F, Ong H, Chemtob S, and Hardy P. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization. Invest Ophthalmol Vis Sci 47: 4356-4364, 2006.
232. Nagata Y, Yamamoto Y, and Niki E. Reaction of phos-phatidylcholine hydroperoxide in human plasma: the role of peroxidase and lecithin:cholesterol acyltransferase. Arch Biochem Biophys 329: 24-30, 1996.
233. Nagy L, Tontonoz P, Alvarez JG, Chen H, and Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93: 229-240, 1998.
234. Nakanishi H, Iida Y, Shimizu T, and Taguchi R. Analysis of oxidized phosphatidylcholines as markers for oxidative stress, using multiple reaction monitoring with theoretically expanded data sets with reversed-phase liquid chromatography=tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877: 1366-1374, 2009.
235. Navab M, Anantharamaiah GM, and Fogelman AM. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis. Trends Cardiovasc Med 18: 61-66, 2008.
236. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, and Fogelman AM. D-4F and statins synergize to render HDL antiin-flammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25: 1426-1432, 2005.
237. Navab M, Anantharamaiah GM, Reddy ST, and Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 3: 540-547, 2006.
238. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, and Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42: 1308-1317, 2001.
239. Nguyen T, Sherratt PJ, and Pickett CB. Regulatory mechanisms controlling gene expression mediated by the anti-oxidant response element. Annu Rev Pharmacol Toxicol 43: 233-260, 2003.
240. Nigam S and Schewe T. Phospholipase A(2)s and lipid peroxidation. Biochim Biophys Acta 1488: 167-181, 2000.
241. Niki E, Yoshida Y, Saito Y, and Noguchi N. Lipid perox-idation: Mechanisms, inhibition, and biological effects. Biochem Biophys Res Commun 338: 668-676, 2005.
242. Nilsson J, Calara F, Regnstrom J, Hultgardh-Nilsson A, Ameli S, Cercek B, and Shah PK. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholes-terolemic rabbits. J Am Coll Cardiol 30: 1886-1891, 1997.
243. Nonas S, Birukova AA, Fu P, Xing J, Chatchavalvanich S, Bochkov VN, Leitinger N, Garcia JG, and Birukov KG. Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivo. Crit Care 12: R27, 2008.
244. Nonas S, Miller I, Kawkitinarong K, Chatchavalvanich S, Gorshkova I, Bochkov VN, Leitinger N, Natarajan V, Garcia JG, and Birukov KG. Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury. Am J Respir Crit Care Med 173: 1130-1138, 2006.
245. O'Donnell VB, Eiserich JP, Chumley PH, Jablonsky MJ, Krishna NR, Kirk M, Barnes S, Darley-Usmar VM, and Freeman BA. Nitration of unsaturated fatty acids by nitric oxide-derived reactive nitrogen species peroxynitrite, nitrous acid, nitrogen dioxide, and nitronium ion. Chem Res Toxicol 12: 83-92, 1999.
246. Ohkura N, Hiraishi S, Itabe H, Hamuro T, Kamikubo Y, Takano T, Matsuda J, and Horie S. Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region. Antioxid Redox Signal 6: 705-712, 2004.
247. Oskolkova OV, Afonyushkin T, Leitner A, von SE, Garga-lovic PS, Lusis AJ, Binder BR, and Bochkov VN. ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: Critical role of oxidized sn-2 residues in activation of unfolded protein response. Blood 112: 330-339, 2008.
248. Owens GK, Kumar MS, and Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767-801, 2004.
249. Pagano RE and Longmuir KJ. Phosphorylation, transbi-layer movement, and facilitated intracellular transport of diacylglycerol are involved in the uptake of a fluorescent analog of phosphatidic acid by cultured fibroblasts. J Biol Chem 260: 1909-1916, 1985.
250. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, and Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 98: 800-814, 1996.
251. Palinski W, Miller E, and Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces ath-erogenesis. Proc Natl Acad Sci USA 92: 821-825, 1995.
252. Papadopoulou C, Corrigall V, Taylor PR, and Poston RN. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine 43: 181-186, 2008.
253. Papaiahgari S, Kleeberger SR, Cho HY, Kalvakolanu DV, and Reddy SP. NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2-ARE transcriptional response in pulmonary epithelial cells. J Biol Chem 279: 42302-42312, 2004.
254. Parhami F, Fang ZT, Yang B, Fogelman AM, and Berliner JA. Stimulation of Gs and inhibition of Gi protein functions by minimally oxidized LDL. Arterioscler Thromb Vasc Biol 15: 2019-2024, 1995.
255. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA, and Demer LL. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 17: 680-687, 1997.
256. Parry GC and Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol 159: 5450-5456, 1997.
257. Parthasarathy S and Rankin SM. Role of oxidized low density lipoprotein in atherogenesis. Prog Lipid Res 31: 127-143, 1992.
258. Pegorier S, Stengel D, Durand H, Croset M, and Ninio E. Oxidized phospholipid: POVPC bindstoplatelet-activating-factor receptor on human macrophages. Implications in atherosclerosis. Atherosclerosis 188: 433-443, 2006.
259. Pidkovka NA, Cherepanova OA, Yoshida T, Alexander MR, Deaton RA, Thomas JA, Leitinger N, and Owens GK. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res 101: 792-801, 2007.
260. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA, and Fyfe AI. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 19: 2847-2853, 1999.
261. Pirog KA, Stabinsky Y, and Goldman R. Peprotech. Cyto-kine index. Edited by Stabinsky Y and Goldman R. Rocky Hill, New Jersey USA: PeproTech Inc., 2006.
262. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, and Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a pro-thrombotic phenotype. Nat Med 13: 1086-1095, 2007.
263. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Febbraio M, Hajjar DP, Silverstein RL, Hoff HF, Salomon RG, and Hazen SL. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 277: 38517-38523, 2002.
264. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, and Hazen SL. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 277: 38503-38516, 2002.
265. Poliakov E, Brennan ML, Macpherson J, Zhang R, Sha W, Narine L, Salomon RG, and Hazen SL. Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo. FASEB J 17: 2209-2220, 2003.
266. Poliakov E, Meer SG, Roy SC, Mesaros C, and Salomon RG. Iso[7]LGD2-protein adducts are abundant in vivo and free radical-induced oxidation of an arachidonyl phospholipid generates this D series isolevuglandin in vitro. Chem Res Toxicol 17: 613-622, 2004.
267. Pontsler AV, St.Hilaire A, Marathe GK, Zimmerman GA, and McIntyre TM. Cyclooxygenase-2 is induced in mono-cytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem 277: 13029-13036, 2002.
268. Pratico D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Rokach J, Maclouf J, Violi F, and FitzGerald GA. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100: 2028-2034, 1997.
269. Pratico D, Tangirala RK, Horkko S, Witztum JL, Palinski W, and FitzGerald GA. Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F(2alpha)-VI levels and the extent of atherosclerosis in ApoE-deficient mice: Modulation by vitamin E. Blood 97: 459-464, 2001.
270. Qiao J, Huang F, and Lum H. PKA inhibits RhoA activation: A protection mechanism against endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 284: L972-L980, 2003.
271. Qiao J, Huang F, Naikawadi RP, Kim KS, Said T, and Lum H. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am J Physiol Lung Cell Mol Physiol 291: L91-101, 2006.
272. Qin J, Goswami R, Balabanov R, and Dawson G. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res 85: 977-984, 2007.
273. Radi R, Beckman JS, Bush KM, and Freeman BA. Perox-ynitrite-induced membrane lipid peroxidation: the cyto-toxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288: 481-487, 1991.
274. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, and Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 4: 211-221, 2006.
275. Ravandi A, Babaei S, Leung R, Monge JC, Hoppe G, Hoff H, Kamido H, and Kuksis A. Phospholipids and oxopho-spholipids in atherosclerotic plaques at different stages of plaque development. Lipids 39: 97-109, 2004.
276. Reaven PD. Mechanisms of atherosclerosis: role of LDL oxidation. Adv Exp Med Biol 366: 113-128, 1994.
277. Reddy S, Hama S, Grijalva V, Hassan K, Mottahedeh R, Hough G, Wadleigh DJ, Navab M, and Fogelman AM. Mitogen-activated protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce monocyte chemotactic activity in human aortic endothelial cells. J Biol Chem 276: 17030-17035, 2001.
278. Reddy ST, Nguyen JT, Grijalva V, Hough G, Hama S, Navab M, and Fogelman AM. Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models. Arterioscler Thromb Vasc Biol 24: 1676-1681, 2004.
279. Roberts II LJ, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, and Morrow JD. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273: 13605-13612, 1998.
280. Roberts LJ and Fessel JP. The biochemistry of the iso-prostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 128: 173-186, 2004.
281. Roberts LJ and Milne GL. Isoprostanes. J Lipid Res 50 Suppl: S219-S223, 2009.
282. Roberts LJ and Morrow JD. Products of the isoprostane pathway: Unique bioactive compounds and markers of lipid peroxidation. Cell Mol Life Sci 59: 808-820, 2002.
283. Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, Kastelein JJ, and Tsimikas S. Oxidized low-density lipoprotein in children with familial hyper-cholesterolemia and unaffected siblings: Effect of pravas-tatin. J Am Coll Cardiol 47: 1803-1810, 2006.
284. Ron D and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529, 2007.
285. Rouhanizadeh M, Hwang J, Clempus RE, Marcu L, Lasse-gue B, Sevanian A, and Hsiai TK. Oxidized-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine induces vascular endothelial superoxide production: Implication of NADPH oxidase. Free Radic Biol Med 39: 1512-1522, 2005.
286. Ryter SW, Alam J, and Choi AM. Heme oxygenase-1= carbon monoxide: from basic science to therapeutic applications. Physiol Rev 86: 583-650, 2006.
287. Sabatini K, Mattila JP, Megli FM, and Kinnunen PK. Characterization of two oxidatively modified phospholip-ids in mixed monolayers with DPPC. Biophys J 90: 4488-4499, 2006.
288. Safa O, Hensley K, Smirnov MD, Esmon CT, and Esmon NL. Lipid oxidation enhances the function of activated protein C. J Biol Chem 276: 1829-1836, 2001.
289. Salomon RG. Isolevuglandins, oxidatively truncated phos-pholipids, and atherosclerosis. Ann NY Acad Sci 1043: 327-342, 2005.
290. Salomon RG. Levuglandins and isolevuglandins: Stealthy toxins of oxidative injury. Antioxid Redox Signal 7: 185-201, 2005.
291. Salomon RG, Batyreva E, Kaur K, Sprecher DL, Schreiber MJ, Crabb JW, Penn MS, DiCorletoe AM, Hazen SL, and Podrez EA. Isolevuglandin-protein adducts in humans: Products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim Biophys Acta 1485: 225-235, 2000.
292. Salomon RG, Sha W, Brame C, Kaur K, Subbanagounder G, O'Neil J, Hoff HF, and Roberts LJ. Protein adducts of iso[4]levuglandin E2, a product of the isoprostane pathway, in oxidized low density lipoprotein. J Biol Chem 274: 20271-20280, 1999.
293. Santrock J, Gorski RA, and O'Gara JF. Products and mechanism of the reaction of ozone with phospholipids in unilamellar phospholipid vesicles. Chem Res Toxicol 5: 134-141, 1992.
294. Savaskan NE, Ufer C, Kuhn H, and Borchert A. Molecular biology of glutathione peroxidase 4: From genomic structure to developmental expression and neural function. Biol Chem 388: 1007-1017, 2007.
295. Schenkein HA, Berry CR, Purkall D, Burmeister JA, Brooks CN, and Tew JG. Phosphorylcholine-dependent cross-reactivity between dental plaque bacteria and oxidized low-density lipoproteins. Infect Immun 69: 6612-6617, 2001.
296. Schneider C, Porter NA, and Brash AR. Routes to 4-hydroxynonenal: fundamental issues in the mechanisms of lipid peroxidation. J Biol Chem 283: 15539-15543, 2008.
297. Schnurr K, Belkner J, Ursini F, Schewe T and Kuhn H. The selenoenzyme phospholipid hydroperoxide glutathione peroxidase controls the activity of the 15-lipoxygenase with complex substrates and preserves the specificity of the ox-ygenation products. J Biol Chem 271: 4653-4658, 1996.
298. Schroder M and Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 74: 739-789, 2005.
299. Sekhar KR, Crooks PA, Sonar VN, Friedman DB, Chan JY, Meredith MJ, Starnes JH, Kelton KR, Summar SR, Sasi S, and Freeman ML. NADPH oxidase activity is essential for Keap1=Nrf2-mediated induction of GCLC in response to 2-indol-3-ylmethylenequinuclidin-3-ols. Cancer Res 63: 5636-5645, 2003.
300. Servitja JM, Marinissen MJ, Sodhi A, Bustelo XR, and Gutkind JS. Rac1 function is required for Src-induced transformation. Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. J Biol Chem 278: 34339-34346, 2003.
301. Seyerl M, Bluml S, Kirchberger S, Bochkov VN, Oskolkova O, Majdic O, and Stockl J. Oxidized phospholipids induce anergy in human peripheral blood T cells. Eur J Immunol 38: 778-787, 2008.
302. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, and Witztum JL. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105: 1731-1740, 2000.
303. Shaw PX, Horkko S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, Chen PP, and Witztum JL. Human-derived antioxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 21: 1333-1339, 2001.
304. Shih PT, Brennan ML, Vora DK, Territo MC, Strahl D, Elices MJ, Lusis AJ, and Berliner JA. Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. Circ Res 84: 345-351, 1999.
305. Shih PT, Elices MJ, Fang ZT, Ugarova TP, Strahl D, Territo MC, Frank JS, Kovach NL, Cabanas C, Berliner JA, and Vora DK. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta1 integrin. J Clin Invest 103: 613-625, 1999.
306. Sigal NH and Dumont FJ. Cyclosporin A, FK-506, and ra-pamycin: Pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10: 519-560, 1992.
307. Silaste ML, Rantala M, Alfthan G, Aro A, Witztum JL, Kesaniemi YA, and Horkko S. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol 24: 498-503, 2004.
308. Silva AR, de Assis EF, Caiado LF, Marathe GK, Bozza MT, McIntyre TM, Zimmerman GA, Prescott SM, Bozza PT, and Castro-Faria-Neto HC. Monocyte chemoattractant protein-1 and 5-lipoxygenase products recruit leukocytes in response to platelet-activating factor-like lipids in oxidized low-density lipoprotein. J Immunol 168: 4112-4120, 2002.
309. Singleton PA, Chatchavalvanich S, Fu P, Xing J, Birukova AA, Fortune JA, Klibanov AM, Garcia JG, and Birukov KG. Akt-mediated transactivation of the S1P1 receptor in caveolin-enriched microdomains regulates endothelial barrier enhancement by oxidized phospholipids. Circ Res 104: 978-986, 2009.
310. Singleton PA, Dudek SM, Chiang ET, and Garcia JG. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1=Rac1, and alpha-actinin. FASEB J 19: 1646-1656, 2005.
311. Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, and McIntyre TM. Oxidatively fragmented phosphatidylcho-lines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 266: 11104-11110, 1991.
312. Smyth EM, Grosser T, Wang M, Yu Y, and FitzGerald GA. Prostanoids in health and disease. J Lipid Res 50: 5423-5428, 2009.
313. Song WL, Lawson JA, Reilly D, Rokach J, Chang CT, Giasson B, and FitzGerald GA. Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J Biol Chem 283: 6-16, 2008.
314. Spector AA and Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292: C996-1012, 2007.
315. Spickett CM. Chlorinated lipids and fatty acids: An emerging role in pathology. Pharmacol Ther 115: 400-409, 2007.
316. Spickett CM, Rennie N, Winter H, Zambonin L, Landi L, Jerlich A, Schaur RJ, and Pitt AR. Detection of phospholipid oxidation in oxidatively stressed cells by reversed-phase HPLC coupled with positive-ionization electrospray [correction of electroscopy] MS. Biochem J 355: 449-457, 2001.
317. Spite M, Baba SP, Ahmed Y, Barski OA, Nijhawan K, Pet-rash JM, Bhatnagar A, and Srivastava S. Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem J 405: 95-105, 2007.
318. Spiteller P and Spiteller G. 9-Hydroxy-10,12-octadecadie-noic acid (9-HODE) and 13-hydroxy-9,11-octadecadienoic acid (13-HODE): Excellent markers for lipid peroxidation. Chemistry and Physics of Lipids 89: 131-139, 1997.
319. Srivastava S, Spite M, Trent JO, West MB, Ahmed Y, and Bhatnagar A. Aldose reductase-catalyzed reduction of aldehyde phospholipids. J Biol Chem 279: 53395-53406, 2004.
320. Stafforini DM, Sheller JR, Blackwell TS, Sapirstein A, Yull FE, McIntyre TM, Bonventre JV, Prescott SM, and Roberts LJ. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 281: 4616-4623, 2006.
321. Steinbrecher UP, Fisher M, Witztum JL, and Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: Generation of antibodies specific for derivatized lysine. J Lipid Res 25: 1109-1116, 1984.
322. Steinbrecher UP, Zhang HF, and Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med 9: 155-168, 1990.
323. Stenson WF and Parker CW. Metabolism of arachidonic acid in ionophore-stimulated neutrophils. Esterification of a hydroxylated metabolite into phospholipids. J Clin Invest 64: 1457-1465, 1979.
324. Strauss G, Osen W, and Debatin KM. Induction of apo-ptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 128: 255-266, 2002.
325. Stremler KE, Stafforini DM, Prescott SM, and McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 266: 11095-11103, 1991.
326. Subbanagounder G, Deng Y, Borromeo C, Dooley AN, Berliner JA, and Salomon RG. Hydroxy alkenal phospholipids regulate inflammatory functions of endothelial cells. Vascul Pharmacol 38: 201-209, 2002.
327. Subbanagounder G, Leitinger N, Schwenke DC, Wong JW, Lee H, Rizza C, Watson AD, Faull KF, Fogelman AM, and Berliner JA. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol 20: 2248-2254, 2000.
328. Subbanagounder G, Wong JW, Lee H, Faull KF, Miller E, Witztum JL, and Berliner JA. Epoxyisoprostane and epox-ycyclopentenone phospholipids regulate monocyte che-motactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1 beta. J Biol Chem 277: 7271-7281, 2002.
329. Subramanian VS, Goyal J, Miwa M, Sugatami J, Akiyama M, Liu M, and Subbaiah PV. Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: Studies with platelet-activating factor-acetyl hydrolase-deficient plasma. Biochim Biophys Acta 1439: 95-109, 1999.
330. Sun M, Finnemann SC, Febbraio M, Shan L, Annangudi SP, Podrez EA, Hoppe G, Darrow R, Organisciak DT, Salomon RG, Silverstein RL, and Hazen SL. Light-induced oxidation of photoreceptor outer segment phospholipids generates ligands for CD36-mediated phagocytosis by retinal pigment epithelium: A potential mechanism for modulating outer segment phagocytosis under oxidant stress conditions. J Biol Chem 281: 4222-4230, 2006.
331. Takai Y, Sasaki T, and Matozaki T. Small GTP-binding proteins. Physiol Rev 81: 153-208, 2001.
332. Takayama F, Egashira T, and Yamanaka Y. Effect of di-clofenac, a non-steroidal anti-inflammatory drug, on lipid peroxidation caused by ischemia-reperfusion in rat liver. Jpn J Pharmacol 64: 71-78, 1994.
333. Tallman KA, Kim HY, Ji JX, Szapacs ME, Yin H, McIntosh TJ, Liebler DC, and Porter NA. Phospholipid-protein ad-ducts of lipid peroxidation: Synthesis and study of new biotinylated phosphatidylcholines. Chem Res Toxicol 20: 227-234, 2007.
334. Tapon N and Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 9: 86-92, 1997.
335. Tokumura A, Toujima M, Yoshioka Y, and Fukuzawa K. Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipids. Lipids 31: 1251-1258, 1996.
336. Tokumura A, Tsutsumi T, and Tsukatani H. Transbilayer movement and metabolic fate of ether-linked phospha-tidic acid (1-O-octadecyl-2-acetyl-sn- glycerol-3-phosphate) in guinea pig peritoneal polymorphonuclear leukocytes. J Biol Chem 267: 7275-7283, 1992.
337. Tsimikas S. In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol 101: 34D-42D, 2008.
338. Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, and Witztum JL. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 41: 360-370, 2003.
339. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, and Berger PB. Relationship of IgG and IgM autoantibodies to oxidized low density lipo-protein with coronary artery disease and cardiovascular events. J Lipid Res 48: 425-433, 2007.
340. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kro-nenberg F, Xu Q, Bergmark C, Weger S, Oberhollenzer F, and Witztum JL. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: Five-year prospective results from the Bruneck study. J Am Coll Cardiol 47: 2219-2228, 2006.
341. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, and Strauss BH. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): Short-term and long-term immunologic responses to oxidized low-density li-poprotein. Circulation 109: 3164-3170, 2004.
342. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, and Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 6: 41-53, 1999.
343. Tsimikas S and Witztum JL. The role of oxidized phos-pholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 19: 369-377, 2008.
344. Tuominen A, Miller YI, Hansen LF, Kesaniemi YA, Witz-tum JL, and Horkko S. A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, ap-optotic cells, and atherosclerotic lesions. Arterioscler Thromb Vasc Biol 26: 2096-2102, 2006.
345. Tyurin VA, Tyurina YY, Feng W, Mnuskin A, Jiang J, Tang M, Zhang X, Zhao Q, Kochanek PM, Clark RS, Bayir H, and Kagan VE. Mass-spectrometric characterization of phos-pholipids and their primary peroxidation products in rat cortical neurons during staurosporine-induced apoptosis. J Neurochem 107: 1614-1633, 2008.
346. Tyurina YY, Serinkan FB, Tyurin VA, Kini V, Yalowich JC, Schroit AJ, Fadeel B, and Kagan VE. Lipid antioxidant, etoposide, inhibits phosphatidylserine externalization and macrophage clearance of apoptotic cells by preventing phosphatidylserine oxidation. J Biol Chem 279: 6056-6064, 2004.
347. Tyurina YY, Tyurin VA, Epperly MW, Greenberger JS, and Kagan VE. Oxidative lipidomics of gamma-irradiation-induced intestinal injury. Free Radic Biol Med 44: 299-314, 2008.
348. Tyurina YY, Tyurin VA, Zhao Q, Djukic M, Quinn PJ, Pitt BR, and Kagan VE. Oxidation of phosphatidylserine: A mechanism for plasma membrane phospholipid scrambling during apoptosis? Biochem Biophys Res Commun 324: 1059-1064, 2004.
349. Uhlson C, Harrison K, Allen CB, Ahmad S, White CW, and Murphy RC. Oxidized phospholipids derived from ozone-treated lung surfactant extract reduce macrophage and epithelial cell viability. Chem Res Toxicol 15: 896-906, 2002.
350. Vaarala O, Puurunen M, Lukka M, Alfthan G, Leirisalo-RepoM,AhoK,and PalosuoT.Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol 104: 269-274, 1996.
351. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Ananthar-amaiah GM, and Fogelman AM. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49: 2302-2311, 2008.
352. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hui EK, Nayak DP, and Fogelman AM. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 110: 3252-3258, 2004.
353. van Nieuw Amerongen GP, van DS, Vermeer MA, Collard JG, and van Hinsbergh V. Activation of RhoA by thrombin in endothelial hyperpermeability: Role of Rho kinase and protein tyrosine kinases. Circ Res 87: 335-340, 2000.
354. van Nieuw Amerongen GP and van Hinsbergh V. Cytos-keletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 21: 300-311, 2001.
355. Vaneker M, Joosten LA, Heunks LM, Snijdelaar DG, Halbertsma FJ, van EJ, Netea MG, van der Hoeven JG, and Scheffer GJ. Low-tidal-volume mechanical ventilation induces a toll-like receptor 4-dependent inflammatory response in healthy mice. Anesthesiology 109: 465-472, 2008.
356. VanRollins M, Woltjer RL, Yin H, Morrow JD, and Montine TJ. F2-dihomoisoprostanes arise from free radical attack on adrenic acid. J Lipid Res 49: 995-1005, 2008.
357. Vila A, Tallman KA, Jacobs AT, Liebler DC, Porter NA, and Marnett LJ. Identification of protein targets of 4-hydro-xynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. Chem Res Toxicol 21: 432-444, 2008.
358. Vohl MC, Neville TA, Kumarathasan R, Braschi S, and Sparks DL. A novel lecithin-cholesterol acyltransferase an-tioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation. Biochemistry 38: 5976-5981, 1999.
359. Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 38: 189-197, 2001.
360. von Schlieffen E., Oskolkova OV, Schabbauer G, Gruber F, Bluml S, Genest M, Kadl A, Marsik C, Knapp S, Chow J, Leitinger N, Binder BR, and Bochkov VN. Multi-hit inhibition of circulating and cell-associated components of the Toll-like receptor 4 pathway by oxidized phospholipids. Arterioscler Thromb Vasc Biol 29: 356-362, 2008.
361. Vora DK, Fang ZT, Liva SM, Tyner TR, Parhami F, Watson AD, Drake TA, Territo MC, and Berliner JA. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res 80: 810-818, 1997.
362. Waddington E, Sienuarine K, Puddey I, and Croft K. Identification and quantitation of unique fatty acid oxidation products in human atherosclerotic plaque using high-performance liquid chromatography. Anal Biochem 292: 234-244, 2001.
363. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, Kensler TW, and Talalay P. Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 101: 2040-2045, 2004.
364. Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL, Lucas RM, Nakai J, Smart EJ, Vora DK, and Berliner JA. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arter-ioscler Thromb Vasc Biol 23: 1197-1203, 2003.
365. Walton KA, Gugiu BG, Thomas M, Basseri RJ, Eliav DR, Salomon RG, and Berliner JA. A role for neutral sphingo-myelinase activation in the inhibition of LPS action by phospholipid oxidation products. J Lipid Res 47: 1967-1974, 2006.
366. Walton KA, Hsieh X, Gharavi N, Wang S, Wang G, Yeh M, Cole AL, and Berliner JA. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn- glycero-3-phosphor-ylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 278: 29661-29666, 2003.
367. Warabi E, Takabe W, Minami T, Inoue K, Itoh K, Yama-moto M, Ishii T, Kodama T, and Noguchi N. Shear stress stabilizes NF-E2-related factor 2 and induces anti-oxidant genes in endothelial cells: Role of reactive oxygen=nitrogen species. Free Radic Biol Med 42: 260-269, 2007.
368. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, and Berliner JA. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte=endothelial interactions and evidence for their presence in vivo. J Biol Chem 272: 13597-13607, 1997.
369. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, and Berliner JA. Effect of platelet activating factoracetylhy-drolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95: 774-782, 1995.
370. Watson AD, Subbanagounder G, Welsbie DS, Faull KF, Navab M, Jung ME, Fogelman AM, and Berliner JA. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J Biol Chem 274: 24787-24798, 1999.
371. Weinstein EA, Li H, Lawson JA, Rokach J, FitzGerald GA, and Axelsen PH. Prothrombinase acceleration by oxida-tively damaged phospholipids. J Biol Chem 275: 22925-22930, 2000.
372. Wenk J, Schuller J, Hinrichs C, Syrovets T, Azoitei N, Podda M, Wlaschek M, Brenneisen P, Schneider LA, Sabi-walsky A, Peters T, Sulyok S, Dissemond J, Schauen M, Krieg T, Wirth T, Simmet T, and Scharffetter-Kochanek K. Overexpression of phospholipid-hydroperoxide glutathi-one peroxidase in human dermal fibroblasts abrogates UVA irradiation-induced expression of interstitial collagenase= matrix metalloproteinase-1 by suppression of phosphati-dylcholine hydroperoxide-mediated NFkappaB activation and interleukin-6 release. J Biol Chem 279: 45634-45642, 2004.
373. White CR, Datta G, Zhang Z, Gupta H, Garber DW, Mishra VK, Palgunachari MN, Handattu SP, Chaddha M, and Anantharamaiah GM. HDL therapy for cardiovascular diseases: The road to HDL mimetics. Curr Atheroscler Rep 10: 405-412, 2008.
374. Winterbourn CC, van den Berg JJ, Roitman E, and Kuypers FA. Chlorohydrin formation from unsaturated fatty acids reacted with hypochlorous acid. Arch Biochem Biophys 296: 547-555, 1992.
375. Wittchen ES, Worthylake RA, Kelly P, Casey PJ, Quilliam LA, and Burridge K. Rap1 GTPase inhibits leukocyte transmigration by promoting endothelial barrier function. J Biol Chem 280: 11675-11682, 2005.
376. Wittwer J and Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 77: 67-77, 2007.
377. Wondrak GT, Jacobson MK, and Jacobson EL. Endogenous UVA photosensitizers: Mediators of skin photodamage and novel targets for skin photoprotection. Photochem Photobiol Sci 5: 215-237, 2006.
378. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, and Yamamoto M. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 28: 2758-2770, 2008.
379. Yang Y, Cheng JZ, Singhal SS, Saini M, Pandya U, Awasthi S, and Awasthi YC. Role of glutathione S-transferases in protection against lipid peroxidation. Overexpression of hGSTA2-2 in K562 cells protects against hydrogen peroxide-induced apoptosis and inhibits JNK and caspase 3 activation. J Biol Chem 276: 19220-19230, 2001.
380. Yeh M, Cole AL, Choi J, Liu Y, Tulchinsky D, Qiao JH, Fishbein MC, Dooley AN, Hovnanian T, Mouilleseaux K, Vora DK, Yang WP, Gargalovic P, Kirchgessner T, Shyy JY, and Berliner JA. Role for sterol regulatory element-binding protein in activation of endothelial cells by phospholipid oxidation products. Circ Res 95: 780-788, 2004.
381. Yeh M, Gharavi NM, Choi J, Hsieh X, Reed E, Mouilles-seaux KP, Cole AL, Reddy ST, and Berliner JA. Oxidized phospholipids increase interleukin 8 (IL-8) synthesis by activation of the c-src=signal transducers and activators of transcription (STAT)3 pathway. J Biol Chem 279: 30175-30181, 2004.
382. Yeh M, Leitinger N, de MR, Onai N, Matsushima K, Vora DK, Berliner JA, and Reddy ST. Increased transcription of IL-8 in endothelial cells is differentially regulated by TNFalpha and oxidized phospholipids. Arterioscler Thromb Vasc Biol 21: 1585-1591, 2001.
383. Yin H, Brooks JD, Gao L, Porter NA, and Morrow JD. Identification of novel autoxidation products of the omega-3 fatty acid eicosapentaenoic acid in vitro and in vivo. J Biol Chem 282: 29890-29901, 2007.
384. Yoshida T, Gan Q, and Owens GK. Kruppel-like factor 4, Elk-1, and histone deacetylases cooperatively suppress smooth muscle cell differentiation markers in response to oxidized phospholipids. Am J Physiol Cell Physiol 295: C1175-C1182, 2008.
385. Yoshimi N, Ikura Y, Sugama Y, Kayo S, Ohsawa M, Ya-mamoto S, Inoue Y, Hirata K, Itabe H, Yoshikawa J, and Ueda M. Oxidized phosphatidylcholine in alveolar mac-rophages in idiopathic interstitial pneumonias. Lung 183: 109-121, 2005.
386. Yurkova I, Huster D, and Arnhold J. Free radical fragmentation of cardiolipin by cytochrome c. Chem Phys Lipids 158: 16-21, 2009.
387. Zagol-Ikapitte I, Masterson TS, Amarnath V, Montine TJ, Andreasson KI, Boutaud O, and Oates JA. Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem 94: 1140-1145, 2005.
388. Zhan X, Brown B, Slobod KS, and Hurwitz JL. Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporine. Transplantation 76: 739-740, 2003.
389. Zhang DD and Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23: 8137-8151, 2003.
390. Zhang Q, Sitzman LA, Al-Hassani M, Cai S, Pollok KE, Travers JB, and Hingtgen CM. Involvement of platelet-activating factor in ultraviolet B-induced hyperalgesia. J Invest Dermatol 129: 167-174, 2009.
391. Zhang Q, Southall MD, Mezsick SM, Johnson C, Murphy RC, Konger RL, and Travers JB. Epidermal peroxisome proliferator-activated receptor gamma as a target for ultraviolet B radiation. J Biol Chem 280: 73-79, 2005.
392. Zhang W and Salomon RG. Oxidized phospholipids, iso-levuglandins, and atherosclerosis. Mol Nutr Food Res 49: 1050-1062, 2005.
393. Zheng Y. Dbl family guanine nucleotide exchange factors. Trends Biochem Sci 26: 724-732, 2001.
394. Zhou J, Lhotak S, Hilditch BA, and Austin RC. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 111: 1814-1821, 2005.
395. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, and Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arter-ioscler Thromb Vasc Biol 21: 108-114, 2001.
396. ZimmanA, Mouillesseaux KP, Le T,Gharavi NM, Ryvkin A, Graeber TG, Chen TT, Watson AD, and Berliner JA. Vascular endothelial growth factor receptor 2 plays a role in the activation of aortic endothelial cells by oxidized phospho-lipids. Arterioscler Thromb Vasc Biol 27: 332-338, 2007.